Pharmacokinetics of non-intravenous formulations of fentanyl. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of non-intravenous formulations of fentanyl.

Pharmacokinetics of non-intravenous formulations of fentanyl.

http://www.wikidata.org/entity/Q38055713

about

Fentanyl for neuropathic pain in adults Daily application of transdermal fentanyl patches in patients receiving hyperbaric oxygen therapy.Fentanyl for neuropathic pain in adults.Cancer pain management: what's new?Clinical and pharmacokinetic considerations of novel formulations of fentanyl for breakthrough cancer pain.Oromucosal film preparations: points to consider for patient centricity and manufacturing processes.Pharmacodynamics and clinical efficacy of fentanyl iontophoretic transdermal system for post-operative pain in hospitalized patients.Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain.Pain management in the acute care setting: Update and debates.Fentanyl Formulations in the Management of Pain: An Update.Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.Efficacy of fentanyl transdermal patch in pain control after lower third molar surgery: A preliminary study.Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers Opioid Resistance Associated with CYP3A4 Hyperactivity and COMT Polymorphism in an Oncological Patient.Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.Quantitative determination of fentanyl in newborn pig plasma and cerebrospinal fluid samples by HPLC-MS/MS.Can fentanyl transdermal patches prevent the cutaneous hyperpigmentation related to radiotherapy in patients with cancer?Pharmacokinetics of a Transdermal Fentanyl Solution in Suffolk Sheep (Ovis aries).A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.Letter to the editor: pharmacokinetics of non-intravenous formulations of fentanyl.[Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].Making a difference: Pragmatic paediatric pain management.Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic.Management of Pain in the Emergency Department

P2860

Q24187562-BC746E1A-CB3E-411C-BF5E-D94690F86273 Q33462518-725E5A88-85EF-40B0-B1E9-84F7B38010A9 Q34542356-DEC309EE-D767-4FE4-8436-2383E894A6F0 Q38086150-AAC1BDEA-F7D8-4B2D-9969-11635305A94A Q38263244-55715011-DFD9-4D0A-AAB3-99035EE07565 Q38630904-9F45CCD8-BA00-48C3-AAA9-7A235E21DBAC Q38632685-2B2744A5-5D8D-4EE8-8100-DAEF918293EE Q38688708-1B941022-9BFA-403D-B00F-79DB7F97AF0F Q38786011-3F986D6D-0BD5-45CE-B9CA-B58A11F6E559 Q38803578-596A083E-0294-4C61-9565-0C0ADB599991 Q39197889-4CB60538-D40E-49A1-BCEE-FA5BA342F269 Q39199331-4801C383-D12B-4DA8-B6E7-AA2BABF3A137 Q40976853-36197C50-E14D-4536-AF40-F0E1664C39B1 Q41368701-5483874A-2AB0-473A-8B7A-1556CCF9DF31 Q43365844-7E1F427B-A321-4671-82E7-5D51F320A639 Q47227162-F8A0DF8F-7D6F-4957-A57B-A85DF064521F Q47738191-EC824C42-53AC-4E43-A49D-85A202FE8C97 Q47811826-EA5A049A-019C-40F1-9BCA-319819F55427 Q47990137-1D37A734-6CA7-4E70-ADA5-1F4CFBB4C700 Q48010349-89C8300C-9DBD-4B0C-90D9-BB90C242FD1B Q48020449-09759328-3C48-4BCB-8D94-0D8BEA40D2DA Q51737999-A140AB6F-9394-4407-8F99-8B1932CD9437 Q54150779-DE42075E-8676-45CC-8A77-45996B968484 Q55022470-8C747A45-B9FA-43CC-82EF-765665C398C0 Q58997832-DBD3743E-C35F-4CD8-B7A5-043FE14E80DC

P2860

Pharmacokinetics of non-intravenous formulations of fentanyl.

http://www.wikidata.org/entity/Q38055713

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetics of non-intravenous formulations of fentanyl.

@en

type

label

Pharmacokinetics of non-intravenous formulations of fentanyl.

@en

prefLabel

Pharmacokinetics of non-intravenous formulations of fentanyl.

@en

P1433

Q38055713-5AB68F30-1876-4270-A98D-4B7063BA3E1E

P1476

Q38055713-F99092D0-8AD7-4845-9F9D-47F755980CCF

P2093

Q38055713-1011F8F6-A467-41D7-B34E-AD7CA48EAE3C

Q38055713-184F180E-BF08-40AD-81F4-1F38F45118FC

Q38055713-2319DD0A-4A91-466E-BFC9-C072A5D03A54

Q38055713-CBEBB42F-BCDD-4DC6-8925-29A064DC9B4F

P2860

Q38055713-01A9C07B-7972-4639-B312-C07A70C32EBE

Q38055713-02A7C84D-4304-4D35-9C6B-CAF203A721AA

Q38055713-040356D2-34AC-4619-82F9-D905A1A98EE2

Q38055713-0841E3C2-BAAF-40E9-8939-2DCA7EE5E436

Q38055713-09325153-0CC4-4014-8B41-C53217C9BF81

Q38055713-0B8B6917-4890-41C5-8D9F-5D558177E2E2

Q38055713-1D87631F-4DC4-4DCA-BFB8-206A0826B66B

Q38055713-202895AF-61B6-48EE-88BD-0E3BB72175CC

Q38055713-21F7DBB4-44CB-4D9A-9C84-0CB2F2B29EB4

Q38055713-2224358C-A8B7-4508-9DD7-188E776E9679

P2888

Q38055713-5EAAC9A6-BAEE-4ECC-8F64-ED5C53706456

P304

Q38055713-0DFB4874-3EE8-4635-BA74-E186A59655A0

P31

Q38055713-C440694B-92C2-4C0B-8E09-DD00C9DDD0EF

P356

Q38055713-6C335769-2BD8-4015-9E89-A04D4FE7916E

P433

Q38055713-C50F32A2-4842-4814-9E6F-3A122C0510EC

P478

Q38055713-F56E223E-079F-44EE-8DB7-AF2FF77DFAAD

P50

Q38055713-98378D5C-59D3-47A0-9414-25027AB3B13D

P577

Q38055713-25C3240A-E207-43E3-BAD8-BA3386BBDC85

P5875

Q38055713-0CAC70B3-6C44-4FDD-B0BB-85B5B2C88975

P6179

Q38055713-E2EBF723-C293-4FD8-9BE2-8442288F3547

P698

Q38055713-E826ACD9-2FF1-4237-9719-EF69E11A76FC

P921

Q38055713-6B8C0268-D294-4E27-8DE8-07934AA114FB

P356

S40262-012-0016-7

P1433

Clinical Pharmacokinetics

P1476

Pharmacokinetics of non-intravenous formulations of fentanyl.

@en

P2093

Bruno G Oertel

http://www.w3.org/2001/XMLSchema#string

Carmen Walter

http://www.w3.org/2001/XMLSchema#string

Gerd Geisslinger

http://www.w3.org/2001/XMLSchema#string

Michael J Parnham

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacological profiles of opioid ligands at kappa opioid receptors.

Activity of opioid ligands in cells expressing cloned mu opioid receptors

Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.

A comprehensive review of rapid-onset opioids for breakthrough pain

Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors

The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management: an analysis of pooled data from three randomized, active-controlled clinical stud

Breakthrough pain: definition, prevalence and characteristics.

Pharmacogenomics: translating functional genomics into rational therapeutics.

Cytochrome P450 3A: ontogeny and drug disposition.

Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study

P2888

s40262-012-0016-7

P304

23-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-012-0016-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232705741

http://www.w3.org/2001/XMLSchema#string

P6179

1023465587

http://www.w3.org/2001/XMLSchema#string

P698

23100195

http://www.w3.org/2001/XMLSchema#string

P921